US FDA Form 483 at CTO2 facility
The US FDA issued a Form 483 with seven observations at the CTO2 facility in Bollaram, Hyderabad. Management has responded but resolution timeline is uncertain.
high · management_commentary
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Lenalidomide revenue decline post-2025
Lenalidomide revenue is expected to decline significantly after September-October 2025 as volume restrictions end and competition intensifies.
high · management_commentaryIron sucrose approval delay due to CRL
The company received a complete response letter (CRL) on the API side for iron sucrose, delaying the expected launch.
medium · management_commentaryIndia business underperformance in cardiac and GI segments
Cardiac and gastrointestinal therapy areas are growing slower than the market; management expects recovery but timeline is uncertain.
medium · analyst_question